Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 175   

Articles published

PFE 31.75 +0.62 (2.01%)
price chart
Pfizer, Inc. Invests in Growth... Literally
Pfizer Inc. (NYSE: PFE ) locked up commercial rights to Opko Health's (NYSE: OPK ) long-lasting human growth hormone in a deal worth hundreds of millions of dollars.
Pfizer, OPKO Health Partner on Growth-Hormone Treatment  Wall Street Journal
Pfizer (PFE) Enters Licensing Agreement With Opko (OPK)  Bidness ETC
Related articles »  
Pfizer Is A Great Income Stock On A Pullback (PFE)
Shareholders of pharma giant Pfizer (NYSE:PFE) have made a lot of money in the past few years. The company, which has generally been regarded as a yield play, has seen the value of its shares rise steadily since the stock consolidated under $20 three ...
Pfizer (NYSE:PFE) Obtains Commercial Rights to Human Growth Hormone
Related articles »  
iTeos Therapeutics Announces License and Collaboration with Pfizer Inc. for ...
GOSSELIES, Belgium, Dec. 8, 2014 /PRNewswire/ -- iTeos Therapeutics SA announced today a strategic collaboration with Pfizer Inc. pursuant to which iTeos will license to Pfizer rights to iTeos' pre-clinical compounds targeting Indoleamine 2,3 ...
Latest Top News Stories: Avanir Pharmaceuticals Inc (NASDAQ:AVNR), Pfizer ...  Markets Emerging
Related articles »  
3 Reasons Pfizer, Inc. Could Soar in 2015
Considering what a strong year it's been for health care stocks, especially biotech and pharmaceutical companies, Pfizer's (NYSE: PFE ) 7% year-to-date gains might leave a lot to be desired among shareholders. Pfizer struggled in 2014, as it has in ...
Related articles »  
Pfizer Inc. (PFE) Closes 1.47% Up on the Day for December 17
Dow Jones component Pfizer Inc. ($PFE) saw its stock move 1.47% to $31.12, representing a per-share move of $0.45, on volume of 24.66 million shares for Wednesday.
Related articles »  
5 Things Pfizer, Inc.'s Management Wants You to Know
Pharmaceutical behemoth Pfizer (NYSE: PFE ) delivered its third-quarter earnings report late last month and all things considered it was pretty much in-line with Wall Street's expectations.
Pfizer Reports Statistically Significant Results for Nerve-Pain Treatment
Pfizer Inc. said a study of its pregabalin controlled-release treatment showed patients taking it for nerve pain showed improvement compared with those who took a placebo.
Pfizer Reports Results From Phase 3 Trial Evaluating Pregabalin CR Formulation  Nasdaq
Related articles »  
OPKO Health (OPK), Pfizer (PFE) Enter Agreement on Long-Acting Human ...
OPKO Health, Inc. (NYSE: OPK) and Pfizer Inc. (NYSE: PFE) announced today that they have entered into a worldwide agreement for the development and commercialization of OPKO's long-acting hGH-CTP for the treatment of growth hormone deficiency ...
Pfizer Inc. (PFE) Closes 0.66% Down on the Day for December 11
Dow Jones component Pfizer Inc. (PFE) saw its stock move -0.66% to $31.65, representing a per-share move of $0.21, on volume of 24.83 million shares for Thursday.
Related articles »  
One Put, One Call Option To Know About for Pfizer
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Pfizer PFE +1.47% Inc (NYSE: PFE). So this week we highlight one interesting put contract, and one interesting call contract, from ...
Related articles »